Roth Capital analyst Jonathan Aschoff lowered the firm's price target on Moleculin Biotech to $31 from $300 and keeps a Buy rating on the shares following the 1-for-25 reverse stock split. The firm says enrollment in the Phase2b/3 MIRACLE trial is progressing as anticipated, with initial results expected in Q1 of 2026.
